178 related articles for article (PubMed ID: 16357312)
1. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
[TBL] [Abstract][Full Text] [Related]
3. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
[TBL] [Abstract][Full Text] [Related]
4. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
[TBL] [Abstract][Full Text] [Related]
5. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome.
Szapary PO; Bloedon LT; Samaha FF; Duffy D; Wolfe ML; Soffer D; Reilly MP; Chittams J; Rader DJ
Arterioscler Thromb Vasc Biol; 2006 Jan; 26(1):182-8. PubMed ID: 16284192
[TBL] [Abstract][Full Text] [Related]
7. Adiponectin concentrations increase during acute FFA elevation in humans treated with rosiglitazone.
Krzyzanowska K; Mittermayer F; Krugluger W; Roden M; Schernthaner G; Wolzt M
Horm Metab Res; 2007 Oct; 39(10):769-72. PubMed ID: 17952842
[TBL] [Abstract][Full Text] [Related]
8. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
[TBL] [Abstract][Full Text] [Related]
9. Insulin resistance, serum adiponectin, and proinflammatory markers in young subjects with the metabolic syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Kinalska I; Gorska M
Metabolism; 2008 Nov; 57(11):1539-44. PubMed ID: 18940391
[TBL] [Abstract][Full Text] [Related]
10. Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Sharabi Y; Oron-Herman M; Kamari Y; Avni I; Peleg E; Shabtay Z; Grossman E; Shamiss A
Am J Hypertens; 2007 Feb; 20(2):206-10. PubMed ID: 17261469
[TBL] [Abstract][Full Text] [Related]
11. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
12. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
Wang TD; Chen WJ; Lin JW; Chen MF; Lee YT
Am J Cardiol; 2004 Feb; 93(3):362-5. PubMed ID: 14759393
[TBL] [Abstract][Full Text] [Related]
13. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
[TBL] [Abstract][Full Text] [Related]
14. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
Barac A; Campia U; Matuskey LA; Lu L; Panza JA
Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
[TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease.
Yu J; Jin N; Wang G; Zhang F; Mao J; Wang X
Metabolism; 2007 Oct; 56(10):1396-401. PubMed ID: 17884451
[TBL] [Abstract][Full Text] [Related]
16. The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study.
Sarafidis PA; Lasaridis AN; Nilsson PM; Mouslech TF; Hitoglou-Makedou AD; Stafylas PC; Kazakos KA; Yovos JG; Tourkantonis AA
Metabolism; 2005 Sep; 54(9):1236-42. PubMed ID: 16125536
[TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone and pioglitazone similarly improve insulin sensitivity and secretion, glucose tolerance and adipocytokines in type 2 diabetic patients.
Miyazaki Y; DeFronzo RA
Diabetes Obes Metab; 2008 Dec; 10(12):1204-11. PubMed ID: 18476983
[TBL] [Abstract][Full Text] [Related]
18. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome.
Choi KM; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH
Diabetes Res Clin Pract; 2007 Feb; 75(2):235-40. PubMed ID: 16872712
[TBL] [Abstract][Full Text] [Related]
19. Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.
Wagner JA; Larson PJ; Weiss S; Miller JL; Doebber TW; Wu MS; Moller DE; Gottesdiener KM
J Clin Pharmacol; 2005 May; 45(5):504-13. PubMed ID: 15831773
[TBL] [Abstract][Full Text] [Related]
20. Endothelial lipase is increased in vivo by inflammation in humans.
Badellino KO; Wolfe ML; Reilly MP; Rader DJ
Circulation; 2008 Feb; 117(5):678-85. PubMed ID: 18212282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
